ANA is one of the few centers in the region offering experimental treatment options for Alzheimer’s disease.
Dr. Klein argues that physicians should be made aware if pharmacies switch a physician-prescribed product for a biosimilar.
The Diamond Stroke Center is named after one of ANA’s founders, Dr. B. Franklin Diamond.
This bill ensures that patients and physicians are made aware if the pharmacist substitutes a biosimilar product.
Fifteen members of the American Headache Society reviewed the existing literature and developed a standard procedure for nerve blocks.
Dr. Burke is one of ANA’s longest-serving physicians.